Company Profile

Arizeke Pharmaceuticals Inc
Profile last edited on: 5/27/09      CAGE: 1SQL9      UEI:

Business Identifier: Oral delivery of very large molecules, specifically protein and genes
Year Founded
1996
First Award
2003
Latest Award
2005
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

6828 Nancy Ridge Drive Suite 400
San Diego, CA 92121
   (858) 455-6907
   lhouston@arizeke.com
   www.arizeke.com
Location: Single
Congr. District: 52
County: San Diego

Public Profile

Arizeke Pharmaceuticals Inc develops novel technology for oral delivery of very large molecules, specifically protein and genes. Arizeke is focused delivery of therapeutic proteins and genes. Though methods exist for delivering such compounds to various The company’s method to enhance the transport of proteins can be applied to a number of potential therapies.Arizeke Pharmaceuticals has the ability to deliver large therapeutic proteins into the lung interstitial, lymphatic and vascular compartments by producing human fusion proteins. These novel therapies will be used to treat diseases of the lung, in particular cancer metastases to the lung, chronic obstructive pulmonary disease and asthm

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
25-49
Revenue Range
2.5M-5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2005 1 NIH $251,779
Project Title: Quantitation of Pulmonary Delivery of a Therapeutic Protein
2003 1 NIH $107,000
Project Title: Novel Aerosol Delivery System for Proteins
2003 1 NIH $106,307
Project Title: Affinity Maturation and Transcytosis

Key People / Management

  Daniel Henderson -- President

  L L Houston

  Paulo Rangel

  David Sudolsky

Company News

There are no news available.